<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439555</url>
  </required_header>
  <id_info>
    <org_study_id>13748</org_study_id>
    <nct_id>NCT01439555</nct_id>
  </id_info>
  <brief_title>Endothelial Facilitation in Alzheimer's Disease</brief_title>
  <official_title>Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Glass Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study: Patients with mild Alzheimer's Disease will be given three different
      drugs over a 4-month period to try to increase the blood flow to their brains, and improve
      blood vessel and brain function. Each drug can help to open the blood vessels in the brain,
      and together they may be more effective than each drug alone. The hypothesis is that small
      blood vessels secrete substances that maintain the integrity of the brain, and may prevent
      loss of nerve cells leading to Alzheimer's Disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline to 16 weeks</time_frame>
    <description>Measurement of changes to cerebral blood flow (ml/110g/min) in regions of interest as measured using Magnetic Resonance Imaging (MRI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cerebral Blood Flow as Measured by Arterial Spin Labeling During Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Data not available as files corrupted and could not be analyzed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mini Mental State Examination (MMSE) Scores</measure>
    <time_frame>Baseline to 4 weeks, 8 weeks and 16 weeks post-baseline</time_frame>
    <description>Change in mental state as reflected by changes to mean Mini Mental State Examination (MMSE) score as measured 4 weeks, 8 weeks and 16 weeks post-baseline. The MMSE uses a 30 point questionnaire to measure cognitive impairment. The MMSE is scored from 0 to 30,with a score equal to or greater than 24 points indicating normal cognition, a score of 19-23 points indicating mild cognitive impairment, 10-18 points indicating moderate impairment and a score equal to or below 9 indicating severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Assessment Screening Test (CAST)</measure>
    <time_frame>Baseline to 16 weeks post-baseline</time_frame>
    <description>This outcome measured the change in average Cognitive Assessment Screening Test (CAST) scores for the participant group. The CAST is scored from 0 to 40. A higher score indicates better performance, and a lower score indicates worse performance. The participants were given the CAST at baseline, 4 weeks, 8 weeks and 16 weeks post-baseline. The outcome reports on the averaged change for the averaged CAST scores from baseline to 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating Scale (CDR)</measure>
    <time_frame>Baseline to 16 weeks post-baseline</time_frame>
    <description>This outcome measures Clinical Dementia Rating Scale (CDR) scores at baseline (enrollment) and 16 weeks post-enrollment. The Clinical Dementia Rating Scale is scored with a composite scale of 0 to 3, with higher scores indicating lower functional status and lower scores indicating better functional status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale: Cognitive and Modified Version (ADAS-COG)</measure>
    <time_frame>Baseline to 16 weeks post-baseline</time_frame>
    <description>Mean Alzheimer's Disease Assessment Scale: Cognitive Subscale (ADAS-COG) score at baseline and at 16 weeks post-enrollment. The ADAS-COG consists of 11 tasks measuring disturbances of memory, language, praxis, attention and other cognitive abilities. Total scores range from 0 to 70, with higher scores (18 and above) indicating greater cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus)</measure>
    <time_frame>Baseline to 4 weeks, 8 weeks and 16 weeks post-baseline</time_frame>
    <description>The Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus) is a semi-structured instrument to examine four major areas of patient function: General, Cognitive, Behavioral and Activities of Daily Living. It is scored from 1 to 7. A score of 1 indicates marked improvement, 4 indicates no change and 7 indicates marked worsening.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Simvastatin + L-Arginine + Tetrahydrobiopterin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin, 40 mg per day orally</description>
    <arm_group_label>Simvastatin + L-Arginine + Tetrahydrobiopterin</arm_group_label>
    <other_name>Tetrahydrobiopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Arginine</intervention_name>
    <description>L-Arginine, 2 Gm four times per day orally;</description>
    <arm_group_label>Simvastatin + L-Arginine + Tetrahydrobiopterin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrahydrobiopterin</intervention_name>
    <description>Tetrahydrobiopterin 20 mg/kg/day orally</description>
    <arm_group_label>Simvastatin + L-Arginine + Tetrahydrobiopterin</arm_group_label>
    <other_name>Kuvan</other_name>
    <other_name>Sapropterin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have mild Alzheimer's Disease or Mild Cognitive Impairment (MCI);

          -  age between 55-85;

          -  Mini Mental Status Exam (MMSE) between 15-26;

          -  a caregiver who can provide information, and bring patient to the sessions;

          -  no known allergies to any of the medications to be used;

          -  normal renal function; willingness of patient and spouse/responsible caregiver to
             participate.

        Exclusion Criteria:

          -  Significant Psychiatric disorder;

          -  stroke; current use of any of the test medications (e.g., statin, L-Arginine, Kuvan);

          -  phenylketonuria (PKU) ;

          -  elevated serum phenylalanine level (&gt;10 mg/dL);

          -  allergy to any of the medications; current active malignancy;

          -  renal insufficiency (elevated creatinine above 1.3mg/dl);

          -  abnormal liver function (Alanine Aminotransferase (ALT) or Aspartate Transaminase
             (AST) 2x normal);

          -  other serious disease including coronary insufficiency or congestive heart failure,
             carotid stenosis greater than 50%, active peptic ulcer, urinary tract or other active
             infection, cancer (except skin cancer, or 5 years inactive breast or prostate cancer
             )etc.;

          -  pregnancy; or

          -  inability to come to UMass for follow-up. Subjects may continue to take
             anticholinesterase drugs for Alzheimer's Disease (Aricept, Exelon, Razadyne) and/or
             Namenda, if they have been on the drug(s) for at least 3 months. Subjects on levodopa
             and male subjects taking drugs for erectile dysfunction (Viagra, Cialis, Levitra) are
             cautioned regarding hypotension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth R DeGrush, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMass Medical School/ UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 16, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2011</study_first_posted>
  <results_first_submitted>May 23, 2019</results_first_submitted>
  <results_first_submitted_qc>July 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2019</results_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Elizabeth Degrush</investigator_full_name>
    <investigator_title>Assistant Professor, Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Early Alzheimer</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Drug treatment</keyword>
  <keyword>Cerebral blood flow</keyword>
  <keyword>Endothelial facilitation</keyword>
  <keyword>Cognitive improvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT01439555/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
          <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Prospective, open-label, single group assignment, single center study conducted by UMass Medical School at the UMass Memorial Medical Center in Worcester, MA. 11 subjects total were screened and enrolled in this study, 10 subjects completed the study as 1 subject was initially enrolled but was excluded due to not meeting inclusion criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
          <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years of Age</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="6.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI)</title>
        <description>Measurement of changes to cerebral blood flow (ml/110g/min) in regions of interest as measured using Magnetic Resonance Imaging (MRI)</description>
        <time_frame>Baseline to 16 weeks</time_frame>
        <population>Data for 6 participants available. Data file for remaining participants corrupted and could not be retrieved for analysis/reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI)</title>
          <description>Measurement of changes to cerebral blood flow (ml/110g/min) in regions of interest as measured using Magnetic Resonance Imaging (MRI)</description>
          <population>Data for 6 participants available. Data file for remaining participants corrupted and could not be retrieved for analysis/reporting.</population>
          <units>ml/110g/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.621528" spread="0.116513988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6447692" spread="0.070388324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.654822667" spread="0.024032403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.579838667" spread="0.091658076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cerebral Blood Flow as Measured by Arterial Spin Labeling During Magnetic Resonance Imaging (MRI)</title>
        <description>Data not available as files corrupted and could not be analyzed</description>
        <time_frame>Baseline to week 16</time_frame>
        <population>Data files corrupted, analysis not possible</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cerebral Blood Flow as Measured by Arterial Spin Labeling During Magnetic Resonance Imaging (MRI)</title>
          <description>Data not available as files corrupted and could not be analyzed</description>
          <population>Data files corrupted, analysis not possible</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini Mental State Examination (MMSE) Scores</title>
        <description>Change in mental state as reflected by changes to mean Mini Mental State Examination (MMSE) score as measured 4 weeks, 8 weeks and 16 weeks post-baseline. The MMSE uses a 30 point questionnaire to measure cognitive impairment. The MMSE is scored from 0 to 30,with a score equal to or greater than 24 points indicating normal cognition, a score of 19-23 points indicating mild cognitive impairment, 10-18 points indicating moderate impairment and a score equal to or below 9 indicating severe impairment.</description>
        <time_frame>Baseline to 4 weeks, 8 weeks and 16 weeks post-baseline</time_frame>
        <population>Patients were sequentially treated with the HMC-CoA reductase synthesis inhibitor simvastatin (weeks 0-16); L-Arginine (weeks 4-16); and tetrahydrobiopterin (weeks 8-16). The investigators assessed cognitive function with a psychometric battery including the MMSE at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Mini Mental State Examination (MMSE) Scores</title>
          <description>Change in mental state as reflected by changes to mean Mini Mental State Examination (MMSE) score as measured 4 weeks, 8 weeks and 16 weeks post-baseline. The MMSE uses a 30 point questionnaire to measure cognitive impairment. The MMSE is scored from 0 to 30,with a score equal to or greater than 24 points indicating normal cognition, a score of 19-23 points indicating mild cognitive impairment, 10-18 points indicating moderate impairment and a score equal to or below 9 indicating severe impairment.</description>
          <population>Patients were sequentially treated with the HMC-CoA reductase synthesis inhibitor simvastatin (weeks 0-16); L-Arginine (weeks 4-16); and tetrahydrobiopterin (weeks 8-16). The investigators assessed cognitive function with a psychometric battery including the MMSE at each time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="3.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.33" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.55" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Assessment Screening Test (CAST)</title>
        <description>This outcome measured the change in average Cognitive Assessment Screening Test (CAST) scores for the participant group. The CAST is scored from 0 to 40. A higher score indicates better performance, and a lower score indicates worse performance. The participants were given the CAST at baseline, 4 weeks, 8 weeks and 16 weeks post-baseline. The outcome reports on the averaged change for the averaged CAST scores from baseline to 16 weeks.</description>
        <time_frame>Baseline to 16 weeks post-baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Assessment Screening Test (CAST)</title>
          <description>This outcome measured the change in average Cognitive Assessment Screening Test (CAST) scores for the participant group. The CAST is scored from 0 to 40. A higher score indicates better performance, and a lower score indicates worse performance. The participants were given the CAST at baseline, 4 weeks, 8 weeks and 16 weeks post-baseline. The outcome reports on the averaged change for the averaged CAST scores from baseline to 16 weeks.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Dementia Rating Scale (CDR)</title>
        <description>This outcome measures Clinical Dementia Rating Scale (CDR) scores at baseline (enrollment) and 16 weeks post-enrollment. The Clinical Dementia Rating Scale is scored with a composite scale of 0 to 3, with higher scores indicating lower functional status and lower scores indicating better functional status.</description>
        <time_frame>Baseline to 16 weeks post-baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Dementia Rating Scale (CDR)</title>
          <description>This outcome measures Clinical Dementia Rating Scale (CDR) scores at baseline (enrollment) and 16 weeks post-enrollment. The Clinical Dementia Rating Scale is scored with a composite scale of 0 to 3, with higher scores indicating lower functional status and lower scores indicating better functional status.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CDR Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDR Score at 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alzheimer's Disease Assessment Scale: Cognitive and Modified Version (ADAS-COG)</title>
        <description>Mean Alzheimer's Disease Assessment Scale: Cognitive Subscale (ADAS-COG) score at baseline and at 16 weeks post-enrollment. The ADAS-COG consists of 11 tasks measuring disturbances of memory, language, praxis, attention and other cognitive abilities. Total scores range from 0 to 70, with higher scores (18 and above) indicating greater cognitive impairment.</description>
        <time_frame>Baseline to 16 weeks post-baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer's Disease Assessment Scale: Cognitive and Modified Version (ADAS-COG)</title>
          <description>Mean Alzheimer's Disease Assessment Scale: Cognitive Subscale (ADAS-COG) score at baseline and at 16 weeks post-enrollment. The ADAS-COG consists of 11 tasks measuring disturbances of memory, language, praxis, attention and other cognitive abilities. Total scores range from 0 to 70, with higher scores (18 and above) indicating greater cognitive impairment.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADAS-COG Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADAS-COG 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus)</title>
        <description>The Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus) is a semi-structured instrument to examine four major areas of patient function: General, Cognitive, Behavioral and Activities of Daily Living. It is scored from 1 to 7. A score of 1 indicates marked improvement, 4 indicates no change and 7 indicates marked worsening.</description>
        <time_frame>Baseline to 4 weeks, 8 weeks and 16 weeks post-baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
            <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus)</title>
          <description>The Clinical Interview Based Impression of Change + Caregiver Input (CIBIC Plus) is a semi-structured instrument to examine four major areas of patient function: General, Cognitive, Behavioral and Activities of Daily Living. It is scored from 1 to 7. A score of 1 indicates marked improvement, 4 indicates no change and 7 indicates marked worsening.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in CIBIC score from baseline to 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.1" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CIBIC Score from 4 weeks to 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".6" spread=".84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in CIBIC Score from 8 weeks to 16 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.1" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin + L-Arginine + Tetrahydrobiopterin</title>
          <description>Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
Simvastatin: Simvastatin, 40 mg per day orally
L-Arginine: L-Arginine, 2 Gm four times per day orally;
Tetrahydrobiopterin: Tetrahydrobiopterin 20 mg/kg/day orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The data for the MRI measurements (cerebral blood flow) experienced file corruption, rendering segments of data irretrievable and the whole set non-analyzable.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elizabeth DeGrush, DO</name_or_title>
      <organization>UMass Medical School</organization>
      <phone>508-334-1000</phone>
      <email>elizabeth.degrush@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

